Guardant Health
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Guardant Health sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Guardant Health: 9 sponsored US clinical trials, 3 recruiting.
Guardant Health sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. The most-studied condition in this pipeline is Colorectal Cancer, with 3 trials.
Top-decile sponsor footprint
Guardant Health ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
Shield Post-Approval Study Protocol
NCT06880055
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT05935384
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444
Screening for High Frequency Malignant Disease
NCT05117840
Decision Counseling and Follow-up for Shield+ Patients
NCT07620535
Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer
NCT04436393
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
NCT04136002
Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records
NCT03625557
Registry of Guardant360® Use and Outcomes In People With Advanced Cancer
NCT03477474
What is open in the Guardant Health pipeline
3 recruiting of 9 indexed (33% open); 3 completed (33%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Colorectal Cancer (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Guardant Health: open-pipeline peers nationwide
Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Guardant Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
- Adagio Medical · 33% recruiting · 3 trials
Related
What to do with this Guardant Health page
9 registered trials is a research-attention snapshot, not an endorsement of Guardant Health or any single study.
- 3 of Guardant Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Colorectal Cancer is the condition Guardant Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Colorectal Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Guardant Health pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.